Professional Summary
Professional Overview
Bryan Lapel is a seasoned pharmaceutical executive with extensive experience in the central nervous system (CNS) and long-term care (LTC) sectors. As the Senior Business Director at Otsuka Pharmaceutical Companies (U.S.), he is responsible for driving strategic business initiatives and leading high-performing teams to deliver exceptional results.
Experience Summary
Current Role
In his current role as Senior Business Director (CNS) at Otsuka, Bryan is responsible for overseeing the development and execution of comprehensive business strategies to support the company's portfolio of innovative CNS products. He collaborates closely with cross-functional teams to optimize market access, maximize sales performance, and enhance patient outcomes. Under his leadership, the CNS business unit has consistently exceeded revenue targets and solidified Otsuka's position as a leading provider of CNS solutions.
Career Progression
Prior to joining Otsuka, Bryan held notable positions at Avanir Pharmaceuticals and Eli Lilly and Company. As the National Executive Sales Director at Avanir, he led a team of sales professionals in the successful commercialization of the company's CNS portfolio, contributing to significant market share growth. At Eli Lilly, he served as the Executive Business Director for Long-Term Care Accounts in the Midwest region, where he spearheaded strategic initiatives to improve access and utilization of the company's pharmaceutical products among LTC providers.
Throughout his career, Bryan has demonstrated a strong track record of driving business growth, fostering collaborative relationships, and implementing innovative strategies to address the evolving needs of the pharmaceutical industry.
Academic Background
Bryan holds a Bachelor's degree in Business Administration from the University of Indiana, where he graduated with distinction and was recognized for his academic excellence.
Areas of Expertise
- Strategic business development and planning
- Pharmaceutical sales and marketing management
- CNS and long-term care industry expertise
- Cross-functional collaboration and team leadership
- Market access and reimbursement strategies
- Talent development and performance optimization
Professional Impact
Under Bryan's leadership, the CNS business unit at Otsuka has consistently exceeded revenue targets, with a significant increase in market share for the company's key CNS products. He has also been instrumental in strengthening Otsuka's partnerships with healthcare providers and payers, leading to improved access and patient outcomes.
Conclusion
With his extensive experience, strategic acumen, and proven track record of success, Bryan Lapel is a valuable asset to Otsuka Pharmaceutical Companies. As he continues to drive the company's CNS business forward, he remains committed to delivering innovative solutions that positively impact the lives of patients and healthcare professionals.
